Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Revenue - Other
Ratios

Mereo BioPharma (MREO) Receivables - Other (2020 - 2023)

Mereo BioPharma (MREO) has disclosed Receivables - Other for 3 consecutive years, with $2.0 million as the latest value for Q4 2023.

  • On a quarterly basis, Receivables - Other changed N/A to $2.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.0 million, a N/A change, with the full-year FY2023 number at $2.0 million, changed N/A from a year prior.
  • Receivables - Other was $2.0 million for Q4 2023 at Mereo BioPharma, up from $1.9 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $2.0 million in Q4 2023 to a low of $1.3 million in Q4 2020.
  • A 3-year average of $1.7 million and a median of $1.9 million in 2021 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 42.58% in 2021; the steepest drop was 42.58% in 2021.
  • Mereo BioPharma's Receivables - Other stood at $1.3 million in 2020, then skyrocketed by 42.58% to $1.9 million in 2021, then grew by 1.94% to $2.0 million in 2023.
  • Per Business Quant, the three most recent readings for MREO's Receivables - Other are $2.0 million (Q4 2023), $1.9 million (Q4 2021), and $1.3 million (Q4 2020).